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Although melanoma mostly affects the skin, it is notorious for its propensity to easily develop metastasis. Met-
astatic melanoma is highly resistant to a variety of therapies. We examined the anti-metastatic potential of per-
itumoral monotherapy against murine cutaneous B16F10 melanoma with synthetic oligodeoxynucleotides (ODN)
containing unmethylated CpG motifs. We demonstrated that repeated peritumoral injections of CpG ODN signif-
icantly reduced skin tumor size. Peritumoral CpG ODN-treatment of skin tumors prevented the development of
pulmonary B16F10 colonies. Adoptive transfer of splenocytes obtained from CpG ODN-treated mice markedly
reduced the number of previously established pulmonary colonies in recipient naı¨ve mice. T-lymphocyte depletion
studies indicated that the anti-metastatic effect was dependent on both CD4þ and CD8þ T cells. These results
suggest that CpG ODN are promising as a preventive and therapeutic anti-metastatic measure against melanoma.
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Melanoma is the main cause of death due to skin malig-
nancies. Although surgery can be curative for most patients
with early thin melanoma, 5-y survival rates of patients with
high-risk, thick melanoma are as low as 25% despite recent
advances in melanoma therapy (Gray et al, 2002). Da-
carbazine, the most effective, widely used agent, is of lim-
ited value (Cocconi et al, 1992; Kleeberg et al, 1995). Other
attempts to improve the therapeutic response rate by using
high-dose regimens or several combinations of chemother-
apeutic agents, the anti-estrogen drug tamoxifen, and in-
terferon (IFN)a-2b have failed (Falkson et al, 1998). The
prognosis of patients with metastasis to the lung, brain,
or liver is much worse as metastatic melanoma is highly
resistant to chemotherapy, radiotherapy, and biologic
response modifiers like IFNa-2b. The high-dose recombinant
interleukin-2 (IL-2) for the treatment of patients with distant
metastasis of melanoma has been utilized. Its overall ob-
jective response rate was reported to be as small as 16%
(Atkins et al, 1999). On the other hand, 53.6% of patients
with only subcutaneous and/or cutaneous metastases have
responded, compared with 12.4% of patients with metas-
tasis to other organs (Phan et al, 2001). But its toxicities
such as septic shock emerge as a serious problem (Fyfe
et al, 1995; Atkins et al, 1999).
Melanoma is a favorite model for cancer immunotherapy.
Some patients respond to lymphokine-activated killer cells,
which are prepared by in vitro culture of circulating lymph-
oid cells in the presence of IL-2 (Rosenberg et al, 1987). In
other patients, administration of autologous tumor-infiltrat-
ing lymphocytes plus IL-2 results in tumor regression
(Rosenberg et al, 1994). Although the efficacy rates of
these adoptive immunotherapies are limited, these results
suggest that T cells have an important role in anti-tumor
activity.
Human melanoma cells have been reported to be subject
to spontaneous T cell responses against tumor antigens
(Ag) (Andersen et al, 2001; Valmori et al, 2001). A series of
tumor antigenic peptides have been identified for me-
lanoma. These peptides might be suitable candidates for
vaccination therapy. Rosenberg et al (1998) reported that
vaccination with immunodominant peptides from one of the
well-known melanoma-associated Ag, gp100, with later
systemic IL-2 administration induced tumor regression in
patients with advanced melanoma. Moreover, a clinical
study using dendritic cells (DC) pulsed with tumor lysate or
a cocktail of peptides showed manifest objective responses
accompanied by significant regression of metastatic tumors
(Mayordomo et al, 1995). Few melanoma patients, however,
responded to these treatments, whereas in the murine B16
melanoma model these immunotherapy studies had cura-
tive potential. Although the powerful immune responses
may be introduced by immunotherapeutic measures and
these may turn out to be of clinical relevance (Rosenberg
et al, 1998; Reynolds et al, 2003), more efficient strategies
are necessary to expand tumor-specific lymphocytes and to
sustain their anti-tumor activity.
Synthetic oligodeoxynucleotides (ODN) containing un-
methylated CpG motifs (CpG ODN) are immune stimulators.
Abbreviations: Ag, antigen; CTL, cytotoxic T lymphocyte; DCs,
dendritic cells; IFN, interferon; IL, interleukin; NK, natural killer;
ODN, oligodeoxynucleotide; PBS, phosphate-buffered saline; Th, T
helper; TLR, Toll-like receptor; TUNEL, terminal deoxynucleotide
transferase-mediated dUTP nick-end labeling
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Tokunaga et al (1984) initially reported that DNA extracted
from Mycobacterium bovis activated natural killer (NK) cells
to produce IFN and to induce anti-tumor activities and that
particular sequences with 50-CpG-30 motif(s) were essential
for these effects. Later, synthetic CpG ODN were reported
to have similar immunologic effects (Krieg et al, 1995) by
activating innate immunity through toll-like receptor (TLR) 9
(Hemmi et al, 2000). Among several immunomodulatory
effects of CpG ODN, of particular interest is the induction
and activation of type 1 T helper (Th1) cells (Chu et al, 1997;
Shirota et al, 2001) and CD8þ cytotoxic T lymphocytes
(CTL) (Vabulas et al, 2000) through the activation and mat-
uration of DC (Jakob et al, 1998; Sparwasser et al, 1998;
Hartmann et al, 1999), leading to the secretion of IL-12 and
the expression of costimulatory molecules (Shirota et al,
2001). We (Shirota et al, 2000) and Raz’s group (Cho et al,
2000) reported that direct conjugation between CpG ODN
and Ag improved the therapeutic efficacy of CpG ODN in
the treatment of allergies and tumors. We subsequently re-
ported that the underlying mechanisms included enhanced
Ag uptake by DC (Shirota et al, 2001). These advantageous
features of the conjugation between CpG ODN and Ag,
however, would not be applicable to most clinical cases
largely due to the failure to define or purify the tumor Ag.
Novel strategies are essential to focus potent immuno-
stimulatory activities of CpG ODN on tumors without any
preceding knowledge of tumor-specific Ags. Immunothera-
pies for metastatic lesions are particularly promising.
Results
Reduction of skin tumor size by peritumoral treatment
with CpG ODN We first examined whether CpG ODN re-
duced the growth of B16F10 skin tumors. Two to six per-
itumoral injections of CpG ODN were administered over
2 wk and tumor size was measured at different time points.
Six 30 mg injections of CpG ODN caused a significant re-
duction in tumor size at all time points examined, whereas
same dose and time injections of control ODN did not affect
tumor size (Fig 1A). Thus, the growth-inhibitory effect of
CpG ODN was dependent on the CpG motifs. The inhibitory
effects on skin tumor growth required more than two injec-
tions of CpG ODN (Fig 1A). A dose–response study indi-
cated that at least 10 mg of CpG ODN was required to
significantly reduce tumor size (Fig 1B). When CpG ODN
were injected into the tumor-free left flank, there were no
inhibitory effects on skin tumor growth.
Induction of skin tumor apoptosis by CpG ODN-treat-
ment is associated with CD8þ T cell inﬁltration Histo-
logic examination was conducted to investigate how
peritumoral CpG treatment exerted anti-tumoral activity.
Tumors treated with phosphate-buffered saline (PBS) alone
had a well-demarcated mass of melanoma cells with clear
cytoplasm, atypical nuclei, and fine melanins. Treatment
with control ODN produced few necrotic islands due to
tumor destruction (Fig 2A). Treatment with CpG ODN in-
duced numerous islands of necrosis inside the CpG ODN-
treated tumors (Fig 2B) with infiltration of CD8þ cells around
the necrotic islands (Fig 2C). There were few CD8þ cells in
the skin tumors treated with control ODN or PBS alone. A
terminal deoxynucleotide transferase-mediated dUTP nick-
end labeling (TUNEL) assay revealed apoptotic cells in CpG
ODN-treated skin tumors (Fig 2D).
CpG ODN-treatment of skin tumors prevents the devel-
opment of B16F10 pulmonary colonies We next investi-
gated whether CpG ODN-treatment of B16F10 skin tumors
reduced the number of pulmonary B16F10 colonies in the
same mouse model. The skin tumor-laden mice treated with
CpG ODN as described above received an additional in-
jection of 2  105 B16F10 cells via the tail vein on the first
day of CpG ODN-treatment. Six peritumoral injections of
CpG ODN were administered. Two weeks after the injection
of B16F10 cells via tail vein, the number of pulmonary col-
onies was determined. Peritumoral injection of 10 mg CpG
ODN, but not control ODN, inhibited the development of
pulmonary colonization (Fig 3A). The same dose of CpG
ODN injected into the opposite side of the flank from the
tumor, which failed to inhibit skin tumor growth (Fig 1B),
suppressed pulmonary metastasis (Fig 3A). When smaller
doses (3 mg) of CpG ODN were inoculated, however,
only those injected into the skin adjacent to, but not dis-
tant from, tumor sites inhibited pulmonary colonization
(Fig 3B and C).
Figure1
Repeated peritumoral injections of CpG ODN inhibited the growth
of previously established B16F10 skin tumors. (A) 30 mg of CpG
ODN were injected two times (&), three times (  ), four times (  ), five
times ( 4 ), and six times ( 5 ) intradermally at the margin of the es-
tablished B16F10 skin tumor. Three or more injections (’) were re-
quired to significantly reduce tumor growth. (B) A dose–response study
(30 mg ( ), 10 mg ( ), 3 mg ( ), and 1 mg ( ) CpG ODN) was performed.
The findings indicated that 10 or more mg of CpG ODN were required to
obtain a statistically significant inhibition of skin tumor growth. Per-
itumoral treatment with control ODN (  ) or PBS (’), or CpG ODN-
treatment at the tumor-free left flank ( ) did not significantly affect
anti-tumoral activity. Each group represents three mice.
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Figure 2
Destruction of B16F10 skin melanoma by peritu-
moral CpG ODN-treatment via an apoptotic mech-
anism was associated with CD8þ T cell infiltration.
(A and B) Skin tumors were injected peritumorally six
times over 2 wk with 30 mg control ODN (A) or 30 mg
CpG ODN (B) (hematoxyline and eosin stain;  50 and
 400). Peritumoral injections of CpG ODN induced
destruction of B16F10 skin tumors. () Islands of ne-
crosis. (C) Immunohistochemically, CD8þ T cells (c)
infiltrated close to the destroyed tumor (  400, the
original magnification). () Island of necrosis. (D)
TUNEL assay disclosed that destruction of the skin
tumor was mediated by an apoptotic mechanism
(  50 and  400, the original magnification). () Is-
lands of necrosis.
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Tumor-specific and tumor-non-specific CpG ODN-medi-
ated inhibition of pulmonary metastasis Immune modu-
lation with CpG ODN results in NK activation and the
release of various cytokines including IL-2, IL-12, and IFNa
(Ballas et al, 1996; Sparwasser et al, 1998; Shimizu et al,
1999; Hafner et al, 2001), although effective CTL are not
induced in the absence of Ag (Carpentier et al, 1999). Re-
peated peritumoral CpG treatment induces CD8þ T cells as
well as NK cells (Kawarada et al, 2001; Heckelsmiller et al,
2002). To examine the roles of such immune cells in the
inhibition of pulmonary melanoma colonization by CpG
ODN, adoptive transfer experiments were performed. The
number of pulmonary colonies was evaluated 2 wk after
melanoma cells were injected intravenously into naı¨ve mice.
One day before (Fig 4A) or 5 d after (Fig 4B) tumor inoc-
ulation, these mice received adoptive transfer of spleno-
cytes from the mice that were treated with CpG ODN.
The CpG ODN-immunized splenocytes transferred to the
naı¨ve mice prior to the melanoma inoculation inhibited pul-
monary metastasis (Fig 4A). In this protocol, the anti-
tumorigenic effector cells were induced independently of
the tumor, because the splenocytes from the mice that had
not borne tumors and yet received the injection of CpG
ODN inhibited the tumor to an extent comparable with that
from mice that received the same injection at peritumoral
sites. These results revealed that tumor-non-specific mech-
anisms were involved in the inhibition of pulmonary metas-
tasis by CpG ODN.
Previously established pulmonary colonies were inhibited
when transferred splenocytes were prepared from mice that
had received peritumoral injections of CpG ODN in the
flank, whereas the tumor-free mice that received the CpG
ODN in the flank failed to develop immune cells that could
inhibit the growth of pulmonary colonies (Fig 4B). Based on
our observation that the intravenously inoculated melanoma
usually grew to form dotted black colonies in the lungs by
the time the CpG ODN-immunized splenocytes were trans-
ferred (data not shown), these results suggest that regres-
sion of the established pulmonary colonies requires tumor-
specific immune responses induced by peritumoral injection
of CpG ODN.
The therapeutic anti-metastatic activity of CpG ODN is
dependent on both primed CD4þ and CD8þ splenocy-
tes Next, we examined whether CD8þ or CD4þ cells were
involved in the CpG ODN-treatment-induced anti-tumor ac-
tivity. Five days after the intravenous inoculation of B16F10
melanoma cells, the mice were injected via the tail veins
with 2  107 splenocytes. Pulmonary colonization was in-
hibited by transfer of the bulk splenocytes or by transfer of
splenocytes enriched with T cells to a similar extent. Splenic
T cells depleted of either CD4þ or CD8þ cells significantly
mitigated the inhibitory effects of CpG ODN-treatment on
the growth of established pulmonary colonies, however, in-
dicating that both CD4þ and CD8þ T cells are essential for
the full-blown anti-metastatic activity of CpG ODN-treat-
ment (Fig 5).
Discussion
The results of this study demonstrated that peritumoral
injections of CpG ODN inhibited the growth of previously
established skin tumors of murine B16F10 melanoma, al-
though the treatment did not induce rejection of the skin
Figure 3
Peritumoral CpG treatment had anti-metastatic activity in an experimental lung metastasis model. (A and B) Repeated six injections of 10 mg
(A) or 3 mg (B) CpG ODN at the margin of B16F10 skin tumor resulted in a statistically significant decrease in pulmonary colonization of intravenously
administered B16F10 melanoma cells (an experimental lung metastasis model). Peritumoral treatment with control ODN, PBS, or CpG ODN (3 mg) at
the tumor-free left flank did not induce statistically significant anti-metastatic activity. Results are presented as mean  SE of n¼ 4 per group.
po0.05 (p¼ 0.02 (A), p¼ 0.03 (B) versus PBS). (C) Photographs of lung tissues with pulmonary colonies of B16F10 melanoma cells that were
obtained from control mouse and mice treated with CpG ODN (3 mg) at the margin of the skin tumor or at the tumor-free left flank.
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tumor as indicated previously by another laboratory (Kawa-
rada et al, 2001). Histologically, the CpG ODN-treatment
induced islands of necrosis inside the skin tumor that were
associated with CD8þ cell infiltration. A TUNEL assay dem-
onstrated that apoptotic DNA fragmentation occurred in the
necrotic lesions. These observations suggest that growth
inhibition is an immunologic event probably dependent on
the action of CD8þ T cells, but that it is not due to a direct
cytotoxic effect. Moreover, CpG ODN-treatment prevented
subsequent experimental metastasis to the lung. The anti-
metastatic effect was transferable to naı¨ve mice. Adoptive
transfer of splenocytes obtained from mice treated with
CpG ODN at the margin of the skin tumor prevented me-
tastasis and inhibited growth of established lung colonies,
whereas splenocytes from tumor-free mice treated with
CpG ODN induced only preventive anti-metastatic activity.
Both CD8þ and CD4þ T cells were essential for the ther-
apeutic anti-metastatic effects.
Several investigators have proposed the use of CpG
ODN for immunotherapy of malignant tumors. In fact, CpG
ODN are effective immune adjuvants as tumor vaccines
(Weiner et al, 1997). Priming of tumor Ag-specific T cells is
essential for the initiation of successful anti-tumor immune
responses. In previous studies (Cho et al, 2000; Davila and
Celis, 2000; Vabulas et al, 2000), an injection of protein Ag
or peptides together with CpG ODN as an adjuvant resulted
in priming CTL. Thus, DC-based immunotherapy is thought
to be promising, but ex vivo manipulation of DC is time- and
cost-intensive. Peritumoral CpG ODN monotherapy for skin
tumors also elicits both NK cell and CTL responses (Kawa-
rada et al, 2001; Heckelsmiller et al, 2002). In murine ne-
uroblastoma and colon carcinoma models (Carpentier et al,
1999; Heckelsmiller et al, 2002), the peritumoral monother-
apy with CpG ODN might induce rejection of established
skin tumors. In this study, peritumoral injections of CpG
ODN delayed the growth of skin melanoma, consistent with
reports by other investigators who found similar effects on
other tumors (Carpentier et al, 1999; Kawarada et al, 2001;
Heckelsmiller et al, 2002), although the treatment did not
induce rejection of the skin tumor.
In most clinical settings, malignant skin tumors can be
surgically removed. Distant metastasis of skin malignancies
such as lung metastasis, however, remains a life-threaten-
ing possibility. Recent papers reported that systemic intra-
venous administration of CpG ODN had preventive anti-
metastatic effects (Hafner et al, 2001; Whitmore et al, 2001).
Because there are some harmful effects of CpG ODN
(Cowdery et al, 1996; Sparwasser et al, 1997), local admin-
istration of less CpG ODN is desirable. Here, skin tumors
were treated with CpG ODN and the anti-metastatic effects
on subsequent pulmonary colonization of melanoma cells
were examined. In our experiment, peritumoral injections
of CpG ODN markedly decreased subsequent pulmonary
colonization. Adoptive transfer of splenocytes from CpG
ODN-treated mice into naı¨ve mice caused a preventive anti-
metastatic activity. This anti-metastatic effect was not
necessarily dependent on the existence of skin tumors in
pre-treated donor mice. There are several reports indicating
that CpG ODN activate NK cells through induction of
cytokines (Tokunaga et al, 1984; Krieg et al, 1995; Ballas
et al, 1996). Depletion of NK cells is reported to abrogate
Figure 4
Adoptive transfer of splenocytes obtained from CpG ODN-treated
mice inhibited pulmonary colonization in naı¨ve recipient mice. (A)
Splenocytes obtained from CpG ODN-treated mice were adoptively
transferred via the tail vein into naı¨ve mice, followed by an intravenous
injection of B16F10 (an experimental lung metastasis model). Preven-
tive anti-metastatic activity was observed regardless of whether CpG
ODN-treatment was performed in tumor-bearing or tumor-free mice.
Results are presented as the mean  SE of n¼ 4 per group. po0.05
(p¼ 0.049 versus PBS). (B) We conducted adoptive transfer of
splenocytes obtained from CpG ODN-treated mice via the tail vein
into naı¨ve mice 5 d after an intravenous injection of B16F10. Peritu-
moral CpG ODN-treatment reduced the number of B16F10 pulmonary
colonies. This therapeutic anti-metastatic activity was not observed
when splenocytes obtained from CpG ODN-treated tumor-free mice
were transferred. Results are presented as mean  SE of n¼ 4 per
group. po0.05 (p¼ 0.03 versus PBS and p¼ 0.02 versus control
ODN).
Figure 5
Both CD4þ and CD8þ Tcells were required for the full-blown anti-
metastatic effects of peritumoral CpG ODN-treatment. Adoptive
transfer after establishment of B16F10 pulmonary colonies was con-
ducted after fractionation of splenocytes obtained from CpG ODN-
treated mice. Depletion of either CD4þ or CD8þ T cells from the
splenocytes resulted in statistically significant inhibition of the thera-
peutic anti-metastatic effects of peritumoral ODN-treatment. Results
are presented as mean  SE of n¼4 or 5 per group. Wspl: whole
spleen cells. po0.05 (p¼ 0.02 versus CD4þ T and p¼ 0.01 versus
CD8þ T).
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the anti-tumor effect of CpG ODN (Carpentier et al, 1999;
Kawarada et al, 2001). The result of a recently published
paper (Hafner et al, 2001) supports the idea that simple CpG
ODN-treatment activates splenic NK cells to induce pre-
ventive anti-metastatic activity.
In this study, adoptive transfer of splenocytes obtained
from mice treated with CpG ODN injections at the margin of
the skin tumor inhibited the growth of established pulmo-
nary colonies in a CD4þ and CD8þ T cell-dependent man-
ner. The mechanism underlying peritumoral CpG ODN-
treatment induction of such therapeutic anti-metastatic ac-
tivity remains unknown. Although in vitro CpG ODN-treat-
ment directly activates human T-lymphocytes to induce
IFNg production (Iho et al, 1999), human T cells at the rest-
ing state do not respond to immunostimulatory DNA-con-
taining CpG motifs (Roman et al, 1997). Ag-presenting cells
such as DC have a key role in the modulation of immune
responses induced by CpG ODN. CpG ODN activate mat-
uration of both murine (Jakob et al, 1998; Hartmann et al,
1999) and human DC (Shirota et al, 2000; Bauer et al, 2001;
Kadowaki et al, 2001). Migration of Langerhans’ cells and
DC from skin is induced by CpG motifs (Ban et al, 2000;
Kawarada et al, 2001). In a previous study, we demonstrat-
ed that CpG ODN-treatment of DC enhanced their Ag up-
take to induce IFNg producing Th1 cells by upregulating the
expression of co-stimulatory molecules (CD40, CD86) and
by provoking IL-12 production (Chu et al, 1997). In addition,
immunization with a major histocompatibility (MHC) class II-
restricted peptide together with CpG ODN as an adjuvant
involves Th1 cells (Stern et al, 2002). In this study, depletion
of either CD8þ or CD4þ cells from the spleen cells used in
the adoptive transfer experiment resulted in significant at-
tenuation of curable anti-metastatic effects on experimental
melanoma metastasis to the lung. Thus, both CD8þ and
CD4þ cells are thought to be required for the full-blown
anti-tumor activity of CpG treatment. Previous observations
suggest that peritumoral CpG ODN-treatment of skin me-
lanoma activates both CD8þ and CD4þ T cells as well as
the NK system (Kawarada et al, 2001; Heckelsmiller et al,
2002). Our results suggest that cytotoxic activities of primed
CD8þ T cells to destroy the tumor by an apoptotic mech-
anism are dependent on CD4þ T cells, especially Th1 cells
(Carpentier et al, 1999).
Taken together, the results indicate that CpG ODN are
potent anti-tumor immunity inducers. CpG ODN have less
toxicity than other adjuvants, such as Freund’s adjuvant
(Jones et al, 1999; Davis et al, 2000). An appropriate dosage
of CpG ODN must be selected, however, because the
quantity and quality of CpG motifs differ among murine and
human systems (Hartmann et al, 2000; Hartmann and Krieg,
2000). The results of the present experiments suggest that
in patients with melanoma, injections of CpG ODN around
the primary lesions before surgery prevent or even inhibit its
metastasis to the lung as well as to other internal organs.
This therapy might be applicable to any tumor metastasis
without preceding knowledge of tumor-specific Ag.
Materials and Methods
Animals and a melanoma cell line Male C57BL/6N mice at 8–10
wk of age were used (Seac Yositomi, Ltd., Fukuoka, Japan). A
murine melanoma cell line, B16F10, was kindly provided by Dr V. J.
Hearing (National Institutes of Health, Bethesda, Maryland). In each
animal experiment, we expanded the cells in Dulbecco’s minimal
essential medium (D-MEM) supplemented with 10% heat-inacti-
vated fetal bovine serum and antibiotics (Sigma Chemical Co., St
Louis, MO).
Studies were performed according to Tohoku University’s
guidelines for animal use and care.
Tumor inoculation and CpG ODN-treatment B16F10 melanoma
cells were cultured and subcutaneously injected 1–2  106
B16F10 cells in 100 mL PBS into the shaved right flanks of naı¨ve
mice. Tumor size was measured with a caliper (Mitutoyo,
Utsunomiya, Japan) and the volumes were estimated using the
formula: p/6  length  width2 (Whitmore et al, 2001). After skin
tumors developed up to 3–5 mm in diameter (about 4–5 d after the
injections), the mice were treated with CpG ODN. We obtained
unmethylated CpG ODN (1826) consisting of 20 bases containing
two CpG motifs (50-TCCATGACGTTCCTGACGTT-30) according to
our previous reports (Shirota et al, 2001, 2002) (Nihon Gene Re-
search Laboratories, Sendai, Japan). The control ODN (1745) was
identical except that the C and G positions were exchanged at two
sites (50-TCCATGAGCTTCCTGAGTCT-30).
The mice were intradermally injected three times per wk with
100 mL PBS or with indicated concentrations of CpG ODN or con-
trol ODN dissolved in 100 mL PBS at two sites in the vicinity of the
skin tumor.
Experimental lung metastasis As an animal model of lung
metastasis, 2  105 B16F10 melanoma cells were inoculated in
500 mL of PBS via tail vein of the mice. Fourteen days after inoc-
ulation, lung tissues were removed and fixed in a 10% formalde-
hyde solution. The number of black colonies on the surface of the
lungs was counted under a dissecting microscope as described by
Yokoyama et al (1986).
Preparations of splenocytes from CpG ODN-treated mice CpG
ODN (3 or 10 mg) or PBS was injected six times every other day to
mice implanted subcutaneously with B16F10 melanoma cells.
Control mice without melanoma cell inoculation were treated with
CpG ODN or PBS. Spleens from these mice were obtained 1 or 2 d
after the sixth CpG ODN-injection. Spleens were minced and red
blood cells were lysed by hypotonic shock solution. Splenocytes
(5  107) were adoptively transferred in 500 mL PBS to recipient
naı¨ve mice via the tail vein.
For fractionation of T cells, splenocytes from tumor-bearing,
CpG-treated mice were pre-incubated with PBS, anti-CD4 (Gk1.5)
(Wilde et al, 1983), or anti-CD8 (3.155) (Sarmiento et al, 1980)
monoclonal antibodies (mAbs) for 1 h at 41C. They were allowed to
react with anti-mouse immunoglobulin (10 mg per mL; Caltag Lab-
oratories, Burlingame, CA), immobilized on plastic plates (Falcon
BD Labware, Franklin Lakes, NJ) for 1 h at 41C, and non-adherent
cells were recovered as enriched T cells, CD8þ or CD4þ T cells,
respectively. Recovered cells (2  107) were intravenously trans-
ferred into recipient mice. Both monoclonal antibodies were used
at a 1:1000 dilution of the ascites form. The efficiency of depletion
was determined by flow cytometry to be greater than 95%.
Immunohistochemical staining Skin tumors were obtained sur-
gically and examined histologically and immunohistochemically.
One half of each sample was embedded in paraffin for H & E stain
and TUNEL assay, and the remainder was snap-frozen in OCT
compound (Sakura Finetechnical Co. Ltd, Tokyo, Japan) for
immunohistochemical staining. Frozen sections (6 mm thick) were
fixed for 10 min in acetone, and incubated with 10% normal rabbit
serum (Nichirei, Tokyo, Japan) for 30 min at room temperature. The
sections were incubated sequentially with biotin-conjugated rat
anti-mouse CD8 (1:100; clone 53-6.7, SouthernBiotech, Birming-
ham, AL) overnight at 41C. The next day, the sections were reacted
with streptoavidin conjugated with peroxidase (Nichirei, Tokyo,
Japan) for 30 min at room temperature. The reaction product was
obtained with 3-amino-9-ethylcarbazole (AEC) (Nichirei).
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TUNEL assay TUNEL of tissue sections was performed using a kit
purchased from Oncogene Research Products (Boston, MA) ac-
cording to the manufacturer’s instructions. Briefly, deparaffinized
tissue sections were treated with 20 mg per mL proteinase K for 20
min at room temperature and inactivated endogenous peroxidase
with 3% H2O2 for 5 min at room temperature. Sections were then
incubated with TdT enzyme and biotin-labeled and -unlabeled de-
oxynucleotides at 371C for 1.5 h in a humid atmosphere. Biotiny-
lated nucleotides were detected using a streptoavidin-HRP
conjugate and the sections were incubated with AEC.
Evaluation of anti-tumor and anti-metastatic effects All exper-
iments were routinely performed in groups of four to five mice
each. Each experiment other than the last experiment was repeat-
ed at least three times. The last T-lymphocyte-depletion experi-
ment was performed twice. Representative data are shown in the
figures, as consistent results were obtained. Statistical analysis
was performed using the Mann–Whitney U test.
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